Clinical Trial Update: Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring a combination of oncolytic virotherapy with tislelizumab and lenvatinib in advanced biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Oncolytic virotherapy
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Advanced Biliary Tract Cancer | Phase 2 | Status: UNKNOWN